The Hayward, Calif.-based company’s Accuryn system is designed to use urinary catheters as diagnostic tools. The device provides real-time measurements of intra-abdominal pressure, urine output and core body temperature and can be integrated into hospital EMR systems, according to Potrero.
The raise has attracted 20 investors, the SEC filing noted. The company closed a $26.6 million Series C funding in July 2018 to help support commercialization of Accuryn.
This article has been corrected regarding Potrero’s use of the proceeds.